The aims of our study were to confirm that ctDNA analysis is feasible in a population of non-metastatic rectal cancer patients, to assess KRAS/BRAF mutations as markers for ctDNA detection, and to explore potential clinical implications of detectable KRAS mutations in ctDNA. The gene discussed is KRAS; the disease is rectal cancer.